Quick Answer
Oric Pharmaceuticals, Inc. reported Total Assets of $408.89 million for the year ending 2025.
- Oric Pharmaceuticals, Inc. showed an increase of +49.2% in Total Assets from 2024 to 2025.
- This data is from Oric Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $85.06 million | Q2 2020: $201.53 million | Q3 2020: $191.66 million | Q1 2021: $283.96 million | Q2 2021: $268.23 million | Q3 2021: $314.18 million | Q1 2022: $275.06 million | Q2 2022: $259.68 million | Q3 2022: $238.00 million | Q1 2023: $226.65 million | Q2 2023: $291.82 million | Q3 2023: $274.34 million | Q1 2024: $350.79 million | Q2 2024: $328.91 million | Q3 2024: $302.07 million | Q1 2025: $242.86 million | Q2 2025: $346.86 million | Q3 2025: $431.19 million.
- Over the full 7 years of available data (2019 to 2025), Oric Pharmaceuticals, Inc.'s Total Assets has grown by 334.6%.
- Historical annual values: Fiscal year 2025: $408.89 million | Fiscal year 2024: $274.14 million | Fiscal year 2023: $252.01 million | Fiscal year 2022: $247.18 million | Fiscal year 2021: $298.64 million | Fiscal year 2020: $299.00 million | Fiscal year 2019: $94.09 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: